B-CLPD with 2 or more B-cell clones: phenotypic differences in individual markers between each neoplastic B-cell subpopulation within each diagnostic disease group
Differing phenotypic marker . | Diagnostic group . | . | . | . | . | . | . | . | . | . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | typCLL, n = 24 . | atypCLL, n = 9 . | HCL, n = 4 . | LPL, n = 4 . | SMZL, n = 3 . | FL, n = 3 . | MCL, n = 2 . | LCL, n = 2 . | Unclassifiable, n = 2 . | Total, %; n = 53 . | |||||||||
| slg | 20∥ | 9∥ | 3∥ | 3∥ | 2§ | 3∥ | 2∥ | 2∥ | 2∥ | 87∥ | |||||||||
| CD5* | 13§ | 8∥ | 1¶ | 2§ | 2§ | 2§ | 1§ | 0 | 2∥ | 58§ | |||||||||
| FMC7 | 8¶ | 6§ | 2§ | 2§ | 1¶ | 0 | 2∥ | 1§ | 1§ | 44¶ | |||||||||
| CD23† | 9¶ | 7§ | 2§ | 2§ | 1¶ | 2§ | 1§ | 0 | 2∥ | 49¶ | |||||||||
| CD22 | 8¶ | 5§ | 1¶ | 1¶ | 1¶ | 1¶ | 1§ | 2∥ | 1§ | 39¶ | |||||||||
| CD19 | 6¶ | 5§ | 2§ | 1¶ | 1¶ | 0 | 1§ | 1§ | 0 | 32¶ | |||||||||
| CD25 | 9¶ | 2 | 2§ | 1¶ | 1¶ | 1¶ | 0 | 1§ | 1§ | 34¶ | |||||||||
| CD11c | 7¶ | 2 | 3∥ | 1¶ | 0 | 1¶ | 0 | 2∥ | 0 | 30¶ | |||||||||
| CD103‡ | 0 | 1 | 3∥ | 0 | 0 | 1¶ | 0 | 0 | 0 | 9 | |||||||||
| CD10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1§ | 0 | 2 | |||||||||
| FSC/SSC | 8¶ | 4¶ | 2§ | 1¶ | 0 | 1¶ | 2∥ | 2∥ | 1§ | 40¶ | |||||||||
Differing phenotypic marker . | Diagnostic group . | . | . | . | . | . | . | . | . | . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | typCLL, n = 24 . | atypCLL, n = 9 . | HCL, n = 4 . | LPL, n = 4 . | SMZL, n = 3 . | FL, n = 3 . | MCL, n = 2 . | LCL, n = 2 . | Unclassifiable, n = 2 . | Total, %; n = 53 . | |||||||||
| slg | 20∥ | 9∥ | 3∥ | 3∥ | 2§ | 3∥ | 2∥ | 2∥ | 2∥ | 87∥ | |||||||||
| CD5* | 13§ | 8∥ | 1¶ | 2§ | 2§ | 2§ | 1§ | 0 | 2∥ | 58§ | |||||||||
| FMC7 | 8¶ | 6§ | 2§ | 2§ | 1¶ | 0 | 2∥ | 1§ | 1§ | 44¶ | |||||||||
| CD23† | 9¶ | 7§ | 2§ | 2§ | 1¶ | 2§ | 1§ | 0 | 2∥ | 49¶ | |||||||||
| CD22 | 8¶ | 5§ | 1¶ | 1¶ | 1¶ | 1¶ | 1§ | 2∥ | 1§ | 39¶ | |||||||||
| CD19 | 6¶ | 5§ | 2§ | 1¶ | 1¶ | 0 | 1§ | 1§ | 0 | 32¶ | |||||||||
| CD25 | 9¶ | 2 | 2§ | 1¶ | 1¶ | 1¶ | 0 | 1§ | 1§ | 34¶ | |||||||||
| CD11c | 7¶ | 2 | 3∥ | 1¶ | 0 | 1¶ | 0 | 2∥ | 0 | 30¶ | |||||||||
| CD103‡ | 0 | 1 | 3∥ | 0 | 0 | 1¶ | 0 | 0 | 0 | 9 | |||||||||
| CD10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1§ | 0 | 2 | |||||||||
| FSC/SSC | 8¶ | 4¶ | 2§ | 1¶ | 0 | 1¶ | 2∥ | 2∥ | 1§ | 40¶ | |||||||||
The 2 cases of unclassified B-CLPD were excluded from this table.
Abbreviations are explained in Table 1.
atypCLL versus HCL (P = .05) and LCL (P = .05).
typCLL versus atypCLL (P = .04).
HCL versus typCLL (P = .01) and atypCLL (P = .05).
Phenotypic difference between each B-cell clone present in 50% to 74% of cases.
Phenotypic difference between each B-cell clone present in 25% to 49% of cases.
Phenotypic difference between each B-cell clone present in 75% to 100% of cases.